Pediatrix Medical Group, INC 10-Q quarterly reports

Pediatrix Medical Group announced a 4.0% increase in net revenue for the second quarter of 2026, driven by acquisitions and same-unit revenue growth, alongside a rise in net income.

Pediatrix Medical Group reports a significant increase in net income and operating income for the first quarter of 2026, driven by acquisitions and improved same-unit revenue.

Pediatrix Medical Group reports a significant turnaround in Q3 and year-to-date 2025, driven by strategic divestitures, improved operational efficiency, and robust cash flow.

Pediatrix Medical Group reports a significant return to profitability in Q2 2025, driven by strategic divestitures and strong same-unit revenue growth.

Pediatrix Medical Group's Q1 2025 net income increased significantly to $20.7 million, driven by same-unit revenue growth and the impact of practice dispositions.

Pediatrix Medical Group's Q3 2024 results reflect a strategic shift towards hospital-based and maternal-fetal medicine, impacting financials with significant impairment charges and restructuring costs.

Pediatrix Medical Group reported a net loss of $153 million for the second quarter of 2024, primarily due to goodwill and asset impairments and restructuring expenses.

Pediatrix Medical Group's first quarter results show a slight revenue increase but a significant drop in net income due to higher operating expenses and restructuring costs.